China Biologic Products Holdings Operating Income

China Biologic Products Holdings (CBPO) currently reports a operating income of $190M as of December 2020. That compares with $160M in the prior-year period — up 18.3% year over year. Use the charts on this page to explore China Biologic Products Holdings's operating income history and peer comparisons.

China Biologic Products Holdings's operating income increased from $160M to $190M — a 18.3% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Biologic Products Holdings reported $190M in operating income as of December 2020. That compares with $160M in the prior-year period — up 18.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.

China Biologic Products Holdings is classified in the Healthcare sector. On operating income, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBPO with unrelated industries.